|
|
|
Volumn 2, Issue 6, 2001, Pages 824-827
|
|
Soretolide: Laboratoires Biocodex
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTICONVULSIVE AGENT;
CARBAMAZEPINE;
CIMETIDINE;
D 2916;
D 3187;
FELBAMATE;
FLUVOXAMINE;
MEXILETINE;
PENTETRAZOLE;
QUINOLONE DERIVATIVE;
REMACEMIDE;
RETIGABINE;
RIFAMPICIN;
SORETOLIDE;
UNCLASSIFIED DRUG;
VALPROIC ACID;
ANTIARRHYTHMIC ACTIVITY;
ANTICONVULSANT ACTIVITY;
CENTRAL NERVOUS SYSTEM DISEASE;
CLINICAL TRIAL;
DISEASE MODEL;
DOSE TIME EFFECT RELATION;
DRUG BIOAVAILABILITY;
DRUG BLOOD LEVEL;
DRUG EFFICACY;
DRUG ELIMINATION;
DRUG HALF LIFE;
DRUG INDICATION;
DRUG MECHANISM;
DRUG METABOLISM;
DRUG POTENCY;
DRUG POTENTIATION;
DRUG SAFETY;
DRUG SYNTHESIS;
DRUG TOLERABILITY;
EPILEPSY;
HUMAN;
LIPID SOLUBILITY;
NONHUMAN;
PHARMACODYNAMICS;
PHASE 2 CLINICAL TRIAL;
REVIEW;
SEX DIFFERENCE;
STRUCTURE ACTIVITY RELATION;
TOXICITY TESTING;
ANIMALS;
ANTICONVULSANTS;
EPILEPSY;
HUMANS;
ISOXAZOLES;
STRUCTURE-ACTIVITY RELATIONSHIP;
|
|
EID: 0034789667
PISSN: 09678298
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (6)
|
|
References (13)
|
